Physician profile
David B Ware
NPI 1801852207
$6,146.15
in general payments reported to CMS, 2019-2025
39 companies · $951 in 2025
The $951 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $743 · 2021: $807 · 2022: $1,124 · 2023: $982 · 2024: $1,094 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.72 |
| Education | $181.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.60 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $813.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $453.64 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $386.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $280.24 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Axsome Therapeutics, INC. | $272.04 | 2023-2025 | Sunosi, Auvelity |
| Jazz Pharmaceuticals INC. | $261.28 | 2019-2025 | Xywav |
| Esperion Therapeutics, INC. | $219.51 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $218.16 | 2020-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $194.72 | 2019-2022 | |
| Nobel Biocare USA | $188.69 | 2022 | |
| 3b Medical, INC. | $165.63 | 2024 | Luna |
| Allergan, INC. | $165.13 | 2019-2020 | |
| Harmony Biosciences LLC | $163.49 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.03 | 2019-2023 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.